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During 1995 to 1999, we collected 1,210 Salmonella isolates; 629 were
from Finnish travelers returning from abroad. These isolates were tested for
susceptibility by determining MICs to ciprofloxacin, nalidixic acid, and seven
additional antimicrobial agents. From 1995 to 1999, the annual proportion of
reduced ciprofloxacin susceptibility (MIC > 0.125 µg/mL) among all travel-
ers’ isolates increased from 3.9% to 23.5% (p<0.001). The increasing trend
was outstanding among the isolates from Southeast Asia; isolates from
Thailand alone increased from 5.6% to 50.0% (p<0.001). The reduced fluo-
roquinolone susceptibility was nonclonal in character and significantly asso-
ciated with multidrug resistance. A point mutation in the quinolone
resistance-determining region of  gyrA was present in all isolates with
reduced susceptibility. These data provide further evidence for the rapid
spread of multidrug-resistant pathogens from one continent to another.
Fluoroquinolones are active drugs against isolates of the
Salmonella species (1). There are several reports, however,
of treatment failures when these antimicrobials have been
used to treat Salmonella infections caused by strains with
reduced fluoroquinolone susceptibility (2-11). Some epidemi-
ologic studies have shown that the number of  Salmonella
isolates with reduced fluoroquinolone susceptibility has
increased, especially in Europe (12,13). Of particular note is
the emergence of quinolone resistance in some clones of the
widespread  Salmonella enterica serotype Typhimurium
definitive phage type 104 (hereafter  S. Typhimurium
DT104) (14,15). For example, Mølbak et al. (14) recently
reported an outbreak caused by a quinolone-resistant  S.
Typhimurium DT104 clone that affected 27 patients in Den-
mark.
Our preliminary report on fluoroquinolone susceptibility
of  Salmonella isolates in Finland showed an increasing
trend in quinolone resistance among isolates classified as
being of foreign origin (16). Our study was performed to con-
tinue the survey of quinolone resistance and multidrug resis-
tance among isolates of S. enterica serotypes. We collected
and analyzed Salmonella isolates from Finnish patients who
acquired the disease either at home or abroad during 1995 to
1999. Special attention was given to delineating the coun-
tries and areas associated with reduced fluoroquinolone sus-
ceptibility in salmonellae from travelers.
 Methods
Salmonella Isolates
In Finland, nearly all  Salmonella isolates recovered
from humans (annually 2,500 to 3,500) are sent to the
National Salmonella Reference Centre of the National Public
Health Institute for typing. In January 1995, a survey was
started to monitor antimicrobial resistance in  Salmonella
isolates sent to the Reference Centre. During 1995 to 1999,
we collected from this material a total of 1,210 Salmonella
isolates, with the aim of including only epidemiologically
unrelated strains. The possible relationship between differ-
ent isolates was judged on the basis of epidemiologic infor-
mation collected from the form that accompanied each
isolate. Isolates recovered from distinct sources were deter-
mined to be epidemiologically unrelated.
Salmonella isolates were divided into two groups accord-
ing to origin of infection. An isolate was designated to be
from a traveler (i.e., foreign), if the patient had reported
travel abroad during 1 month before the specimen date. All
other isolates were designated to be of domestic (i.e., Finn-
ish) origin. Isolates were collected in five phases: starting in
January 1995, we consecutively collected 100 foreign and
100 domestic isolates; starting in September 1996, 200 for-
eign and 200 domestic isolates; and starting in January
1997, in January 1998, and in January 1999, 100 foreign and
100 domestic isolates, respectively.
Susceptibility Testing
MICs of isolates were determined by the standard plate
agar dilution method according to National Committee for
Clinical Laboratory Standards (NCCLS) guidelines (17). The
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quinolones evaluated were ciprofloxacin and nalidixic acid;
the other antimicrobials were ampicillin, cefotaxime, strep-
tomycin, tetracycline, chloramphenicol, trimethoprim, and
sulfamethoxazole. Mueller-Hinton II agar (BBL, Becton
Dickinson and Co., Cockeysville, MD) was used as the cul-
ture media. Staphylococcus aureus American Type Culture
Collection (ATCC) 29213, Escherichia coli ATCC 25922,
E.coli  ATCC 35218, and  Pseudomonas aeruginosa  ATCC
27853 were used as controls in testing for susceptibility.
The breakpoint value for reduced ciprofloxacin suscepti-
bility was chosen as >0.125 µg/mL on the basis of earlier
publications (14) and our recent scatterblot analyses, com-
bined with the sequencing data of the quinolone resistance
determining region (QRDR) of the gyrA gene (18). For other
antimicrobials, MIC breakpoints for resistance used were
those recommended by NCCLS (17). 
Susceptibility data were analyzed by using the
WHONET5 computer program (19,20), available from
www.who.int/emc/WHONET/.
Polymerase Chain Reaction and Sequencing
The QRDR of the gyrA gene was sequenced from isolates
with reduced ciprofloxacin susceptibility, as we reported pre-
viously (18). 
Passenger Statistics
Data concerning the numbers of trips from Finland to
countries of interest (i.e., countries with the largest numbers
of all Salmonella isolates or isolates with reduced ciprofloxa-
cin susceptibility) during the study months were received
from Statistics Finland (www.stat.fi/). 
Statistical Analysis
Data were summarized with numbers and proportions of
Salmonella isolates. Differences in these proportions were
statistically tested by applying logistic regression analysis in
the following way. Differences between years were modeled
as a trend over years. Before doing these analyses, the good-
ness-of-fit of model of trend was tested. Differences between
groups, in trends over years, were analyzed by testing inter-
actions in the models. In addition to assessing crude differ-
ences between origin of isolates, an adjusted comparison
with year as a covariate was done. Differences were quanti-
fied by calculating odds ratios and 95% confidence intervals
(CI) (21). Differences between Salmonella infection rates in
travelers returning from various travel destinations were
statistically tested with Poisson regression analysis and
quantified with infection rates and 95% CI (22); p values
<0.05 were interpreted as significant. Statistical computing
was performed by using the SAS system for Windows, release
8.00/1999 applying LOGISTIC or GENMOD procedures.
Results
Serotype and Origin of Salmonella Isolates
Of 1,210 Salmonella isolates studied, 629 were collected
from persons reporting travel abroad within 1 month before
specimen collection; 581 were classified as of domestic origin.
Of all isolates, 98% were from stools and 2% were from
extraintestinal sources. Ninety different serotypes were
identified. Among the salmonellae isolated from travelers,
S. Enteritidis and S. Typhimurium were the most prevalent
serotypes, accounting for 36.2% and 7.8% of those isolates,
respectively (Table 1). Among the domestic salmonellae,
S. Typhimurium accounted for 37.3% and S. Enteritidis for
17.0% of isolates.
Of the 629 foreign isolates, the country where salmonel-
losis was acquired was identified for 618 isolates. For the
remaining 11 isolates, origin could be traced to the continen-
tal level for 9; the origin of 2 isolates remains unknown.
Table 1. Serotype distribution and reduced ciprofloxacin (CIP) susceptibility (MIC >0.125 µg/mL) among 1,210 Salmonella isolates studied
Serotype
Isolates from Finnish travelers Isolates of Finnish origin All isolates
No. of 
isolates
(% of total)
% CIP MIC 
>0.125 µg/mL
No. of isolates (% 
of total)
% CIP MIC 
>0.125 µg/
mL
No. of  isolates
(% of total)
% CIP MIC 
>0.125 µg/
mL
S. Enteritidis 228 (36.2) 3.5 99 (17) 0 327 (27) 2.4
S. Typhimurium 49 (7.8) 22.4 217 (37.3) 1.4 266 (22) 5.3
S. Hadar 34 (5.4) 32.4 14 (2.4) 21.4 48 (4) 29.2
S. Virchow 27 (4.3) 37.0 13 (2.2) 15.4 40 (3.3) 30.0
S. Montevideo 22 (3.5) 0 15 (2.6) 6.7 37 (3.1) 2.7
S. Newport 18 (2.9) 5.6 13 (2.2) 0 31 (2.6) 3.2
S. Braenderup 18 (2.9) 0 2 (0.3) 0 20 (1.7) 0
S. Infantis 17 (2.7) 5.9 33 (5.7) 0 50 (4.1) 2.0
S. Anatum 17 (2.7) 11.8 4 (0.7) 25.0 21 (1.7) 14.3
S. Panama 11 (1.7) 9.1 4 (0.7) 0 15 (1.2) 6.7
Other serotypes (N=80) 188 (29.9) 11.2 167 (28.7) 1.2 355 (29.3) 6.5
Total 629 (100) 10.5 581 (100) 2.1 1,210 (100) 6.4Research
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Most isolates classified as foreign were from travelers to
Asia and Europe (Table 2). Altogether, the isolates were
obtained from travelers to 53 different countries, with Thai-
land, Spain, and Turkey the most frequent travel destina-
tions (Table 3).
Fluoroquinolone Susceptibility
Among all 1,210 Salmonella isolates, 78 (6.4%) exhibited
reduced susceptibility to ciprofloxacin (MIC >0.125 µg/mL).
These less susceptible isolates consisted of 66 isolates from
travelers and 12 of domestic origin. From 1995 to 1999, the
annual proportion of reduced ciprofloxacin susceptibility
increased from 3.9% to 23.5% (p<0.001) among foreign iso-
lates, and from 0% to 4.1% (p = 0.031) among domestic iso-
lates (Figure, A,B). An increasing trend throughout the
study period was confirmed by logistic regression analysis.
The difference between isolates from travelers and those of
domestic origin was significant, even after adjustment of
year trends (p<0.001). The trends of these groups were not
different (p = 0.684). All isolates with reduced ciprofloxacin
susceptibility were uniformly resistant to nalidixic acid (MIC
>32 µg/mL). Thus, the terms reduced fluoroquinolone sus-
ceptibility and quinolone resistance are used interchange-
ably hereafter. All these isolates were susceptible to
ciprofloxacin according to NCCLS breakpoint recommenda-
tion (MIC <1 µg/mL).
The 78 isolates with reduced ciprofloxacin susceptibility
included 19 different serotypes. The most common were
S. Hadar (17.9% of isolates),  S. Typhimurium (17.9%),
S. Virchow (15.4%), and S. Enteritidis (10.3%).
Quinolone Resistance in Travelers
Isolates with reduced ciprofloxacin susceptibility were
obtained from travelers returning from 17 countries; most
isolates were from Thailand, Israel, and Spain. The
geographic distribution of these isolates by continent is
shown in Table 2, which also presents the annual numbers of
isolates with decreased ciprofloxacin susceptibility. During
the study period, increases in quinolone-resistant isolates
from Asia, taken as a whole, and from Southeast Asia alone,
were statistically significant (p<0.001 for both). Among iso-
lates from Thailand, this increase was especially prominent:
from 1 (5.6%) of 18 in 1995 to 17 (50.0%) of 34 in 1999
(p<0.001) (Figure, C) (Table 4). Based on the estimated num-
bers of trips from Finland (during the time the isolates were
collected) to the five most frequent countries of origin of all
foreign Salmonella isolates, as well as of those with reduced
ciprofloxacin susceptibility, the infection rates by quinolone-
resistant  Salmonella isolates were highest in travelers
returning from Thailand and Malaysia: 0.81 and 0.80 infec-
tions per 1,000 trips, respectively (Table 5). (Although the
total infection rate of salmonellosis was highest [6.7 infec-
tions per 1,000 trips] in Tunisia, the infection rate by
quinolone-resistant  Salmonella isolates was zero.) Despite
the high proportion (58.3%) of reduced ciprofloxacin suscep-
tibility in the 12 isolates from Israel (Table 3), the risk of
acquiring quinolone-resistant salmonellosis was only 0.30
per 1,000 travels to that country (Table 5). Travelers return-
ing from Spain and Estonia had low infection rates by all sal-
monellae, including the quinolone-resistant strains.
Among all 31 isolates with reduced ciprofloxacin suscep-
tibility from Thailand, 13 different serotypes were identified;
the 17 isolates collected during 1999 were divided into 12
serotypes (Table 4). These findings exclude the presence of
one single clone or of a few clones.
Table 2. Number and source of 629 Salmonella isolates from Finnish travelers and the annual numbers of isolates with reduced ciprofloxacin
susceptibility (MIC >0.125 µg/mL), 1995 to 1999
Geographic area All isolates
Isolates with reduced ciprofloxacin susceptibility
Yeara
Total (% of all 
isolates) p valueb
1995 
(102)
1996 
(216)
1997 
(107)
1998 
(102)
1999 
(102)
Africa 86 0 0 2 2 0 4 (4.7) 0.144
America 27 0 0 0 0 1 1 (3.7) 0.132
Asia 292 3 6 8 14 18 49 (16.8) <0.001
  Southeast Asia 147 1 1 6 10 18 36 (24.5) <0.001
  Middle East 93 2 5 1 2 0 10 (10.8) 0.706
  Other areas 52 0 0 1 2 0 3 (5.8) 0.119
Europe 222 1 4 1 0 5 11 (5.0) 0.079
  Mediterranean area 78 1 2 1 0 1 5 (6.4) 0.801
  Canary Islands 60 0 1 0 0 3 4 (6.7) 0.147
  Other areas 84 0 1 0 0 1 2 (2.4) 0.205
Total 629c,d 4c 10 c 11c 17c,e 24 c 66c,e (10.5) <0.001
aThe annual numbers of all isolates from Finnish travelers studied in parentheses.
bThe differences between years were modeled as a trend over years in these analyses. p value shows the statistical significance of this trend.
cSum of the numbers written in bold.
dTwo isolates of unknown origin included.
eOne isolate of unknown origin included.Research
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Nucleotide Sequence Analysis
A base substitution in the QRDR of gyrA at codon 83 or
87 was present in all 78 isolates with reduced ciprofloxacin
susceptibility. The sequence data of mutations in part of
these isolates have been described elsewhere (18). 
Resistance to Other Antimicrobials
Among all 1,210 Salmonella isolates studied, 56 differ-
ent resistance profiles were detected. These profiles were
analyzed separately for the isolates with reduced ciprofloxa-
cin susceptibility and those fully susceptible. As many as
47.4% of the 78 quinolone-resistant isolates had three or
more additional resistance properties, whereas only 11.5% of
the 1,132 quinolone-susceptible isolates were resistant to
three or more antimicrobials (p<0.001).
Of all 629 foreign isolates and 581 domestic isolates,
20.3% and 18.1%, respectively, were resistant to tetracy-
cline. Resistance to sulfamethoxazole was 14.0% among the
foreign isolates and 17.7% among the domestic isolates. Cor-
responding figures were 7.9% and 11.5% for ampicillin and
5.6% and 5.3% for trimethoprim. Of all isolates, 16.9% were
resistant to streptomycin and 8.8% were resistant to
chloramphenicol. There was no resistance to cefotaxime.
Discussion
Our study shows a dramatic increase in the annual pro-
portion of reduced fluoroquinolone susceptibility (from 3.9%
to 23.5%; p<0.001) among all foreign Salmonella isolates in
Finland between 1995 and 1999. The increasing trend was
particularly notable among isolates collected from travelers
returning from Southeast Asia, especially Thailand. More-
over, 27.2% of all 114 Salmonella isolates from Thailand had
reduced fluoroquinolone susceptibility; the proportion of
reduced susceptibility was equal among the 11 isolates from
Malaysia. The common nature of quinolone resistance in
Southeast Asia is illustrated also by our passenger data,
which revealed that a tourist’s risk of acquiring quinolone-
resistant salmonellosis was significantly higher in Thailand
and Malaysia than in other destinations. These results
clearly show that in the era of frequent international connec-
tions, microbes may be easily transmitted from one place to
another. Correspondingly, factors furthering the emergence
and spread of antimicrobial resistance in any country may
soon have an impact on resistance of bacterial pathogens, or
even of normal human flora, in faraway regions, even differ-
ent continents. On this basis, the emergence of antimicrobial
Table 3. List of the most frequent countries of origin of the 629
Salmonella isolates from Finnish travelers and percentage of
reduced ciprofloxacin (CIP) susceptibility (MIC >0.125 µg/mL)
Country/area
No. of isolates
(% of total)
% CIP MIC
 >0.125 µg/mL
Thailand 114 (18.1) 27.2
Spain (incl. 
Canary Islands)
88 (14.0) 6.8
Turkey 69 (11.0) 4.3
Tunisia 37 (5.9) 0
Estonia 32 (5.1) 3.1
Morocco 27 (4.3) 7.4
India 26 (4.1) 7.7
Greece 17 (2.7) 5.9
Indonesia 16 (2.5) 6.3
Cyprus 14 (2.2) 7.1
Dominican 
Republic
14 (2.2) 7.1
Kenya 14 (2.2) 7.1
Sri Lanka 14 (2.2) 7.1
Israel 12 (1.9) 58.3
Malaysia 11 (1.7) 27.3
Russia 11 (1.7) 0
Other areas 
(N=42)
113 (18.0) 4.4
Total 629 (100) 10.5
Figure. Percentage of Salmonella isolates with reduced ciprofloxa-
cin susceptibility (MIC  >0.125 µg/mL) of domestic (Finnish) origin
(A), from Finnish travelers (B), and from Finnish travelers return-
ing from Thailand (C), according to year. Bars represent observed
percentages; the continuous curve represents the predicted trend of
logistic model for the percentages; the dashed curves are 95% confi-
dence intervals for the predictions.Research
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resistance in any part of the world may have a global bearing
and thus deserves universal attention.
When looking for reasons for the rapidly increased
quinolone resistance in our travelers’ Salmonella isolates,
three issues must be considered: transferable resistance,
mutational resistance, and clonal spread. Until now, trans-
ferable resistance to the quinolone antimicrobial group has
been described in one preliminary report (23). As far as we
know, however, transferable fluoroquinolone resistance
appears to be rare in bacteria in vivo. Thus, either clonal
spread or resistance due to mutations in chromosomal genes
remains the potential mechanism accounting for the high
level of reduced fluoroquinolone susceptibility in Southeast
Asia. In Thailand, the possibility of clonal spread as a major
contributing factor was excluded by identification of 13 sero-
types among the quinolone-resistant isolates. In addition,
some of these serotypes contained different antimicrobial
resistance patterns. Based on these data, we conclude that
the reduced fluoroquinolone susceptibility of salmonellae in
Thailand primarily involves mutations in chromosomal
genes. This concept is consistent with our sequencing data:
all 78 Salmonella isolates with reduced fluoroquinolone sus-
ceptibility (31 from Thailand) so far analyzed in our labora-
tory have shown a point mutation leading to an amino acid
change in their QRDR of the gyrA gene. By no means does
this finding exclude the presence of any other additional
resistance mechanisms.
The emergence of mutation-based resistance may be fos-
tered by selection pressure caused by the use of antimicro-
bial agents in either human medicine or agriculture.
Accordingly, the alarming increase in quinolone resistance
observed during the past few years among foodborne patho-
gens (24-27) has aroused speculation that this might be an
effect of the use of quinolones in animal husbandry (14,28).
Indeed, two recent articles (29,30) have shown that enroflox-
acin (a fluoroquinolone used in agriculture) can select Sal-
monella mutants resistant to nalidixic acid and
fluoroquinolones. No part of the world allows quinolones to
be used as growth-promoters, but they have been licensed for
therapeutic use in food animals in many countries. In Asia,
several quinolones, including three fluoroquinolones licensed
for humans (ciprofloxacin, ofloxacin, and norfloxacin), have
been approved for animal use (31). In Europe, none of the
fluoroquinolones licensed for humans are approved for ani-
mal use, although many other quinolone preparations are
allowed for the treatment of livestock, poultry, and fish. The
policy is more strict in the United States, where the only qui-
nolone licensed for food animals is enrofloxacin (32), which is
allowed for treatment of poultry alone (31). Without any
data on the consumption figures of the quinolone antimicro-
bial group, no conclusions can be drawn on a potential link
between the reduced fluoroquinolone susceptibility of salmo-
nellae and the use of quinolones in animal husbandry in the
areas studied. Yet, such a connection is plausible.
On the other hand, the alternative that extensive use of
fluoroquinolones in human disease could be responsible for
the rapidly increased quinolone resistance of salmonellae
seems unlikely, since fluoroquinolones as potent bactericidal
drugs are not particularly prone to select for resistance dur-
ing treatment (33). In direct contrast, treatment with first-
generation quinolones (e.g., nalidixic acid) is known to fur-
ther rapid emergence of resistance in the family of Entero-
bacteriaceae  (34,35). Consequently, widespread use of
nalidixic acid could easily explain the emergence of reduced
fluoroquinolone susceptibility in salmonellae. Again, in the
absence of data on the potential use of nalidixic acid for
treating salmonellosis in Southeast Asia, such an option can
only be hypothesized. The theory is conceivable, however,
considering that according to a recent report (36), nalidixic
acid is frequently used in Thailand in the treatment of dys-
entery because resistance of shigella to other antimicrobial
groups is common. Another topic of major interest involves
Table 4. Serotype distribution of 31 Salmonella isolates with reduced ciprofloxacin susceptibility (MIC >0.125 µg/mL) from Thailand related to year
of isolation
Serotype
1995 1996 1997 1998 1999 Total
(N=18/10)a (N=5/4)a (N=27/12) a (N=30/17)a (N=34/22)a (N=114/31)a
S. Blockley 1 1 2 4
S. Haardt 1 2b 1 4
S. Typhimurium 6b 6
S. Rissen 2 1 3
S. Hadar 1 3 4
S. Enteritidis 2 2
S. Virchow 2b 2
S. Albany 1 1
S. Anatum 1 1
S. Mbandaka 1 1
S. Newport 1 1
S. Panama 1 1
S. Schwarzengrund 1 1
Total 1 1 6 6 17 31
aNumber of all isolates/all serotypes.
bAmong these isolates, two different resistance patterns were observed.Research
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the potential influence of antimicrobial use in travelers for
infections with quinolone-resistant  Salmonella strains.
Unfortunately, data on prophylactic or therapeutic use of
antimicrobials were not collected here.
An increasing incidence of reduced fluoroquinolone sus-
ceptibility in  S. enterica serotypes also became manifest in
Europe during the 1990s. In England and Wales, reduced
ciprofloxacin susceptibility (MIC >0.25 µg/mL) in salmonel-
lae increased from 0.3% to 2.1% during the period 1991 to
1994, affecting primarily S. Hadar and S. Virchow serotypes
(12). Concurrently, reduced ciprofloxacin susceptibility
emerged in the multidrug-resistant clone of S. Typhimurium
DT104, of which 1% in 1994 and 6% in 1995 were quinolone
resistant (15). There are few U.S. reports of quinolone-resis-
tant salmonellae. Only 21 (0.5%) of the 4,008 U.S.  Salmo-
nella isolates collected and analyzed during the years 1994
to 1995 were resistant to nalidixic acid (37). Even among the
multidrug-resistant  S. Typhimurium DT104, quinolone
resistance in the United States has remained rare (24). How-
ever, strains with reduced fluoroquinolone susceptibility are
currently not identified in any microbiologic laboratory
worldwide according to current NCCLS recommendations,
with MIC >4 µg/mL of ciprofloxacin as a breakpoint for resis-
tance (17). These breakpoint values are considered adequate,
as the clinical importance of the reduced fluoroquinolone
susceptibility of salmonellae remains unproven. Neverthe-
less, we recommend that laboratories worldwide aim at rec-
ognizing these less susceptible strains, to reveal their
eventual clinical impact. We suggest that laboratories use
the nalidixic acid screening test (18) or the E-test to aid iden-
tification. 
It is noteworthy that the less susceptible subpopulation
has already undergone one point mutation and thus is
potentially inclined to a second mutation, which could lead
to high-level fluoroquinolone resistance. Admittedly, highly
fluoroquinolone-resistant  Salmonella strains are still
extremely rare, and they are usually counterselected in field
conditions (30). Even so, one can envision that highly fluoro-
quinolone-resistant Salmonella strains, capable of surviving,
will inevitably emerge, if the less susceptible strains become
prevalent and quinolone pressure persists. On this account,
global surveillance of reduced fluoroquinolone susceptibility
of salmonellae is also necessary for epidemiologic reasons.
Simultaneous with the increasing incidence of quinolone
resistance in salmonellae, rapid emergence of fluoroqui-
nolone resistance is occurring in other enteric bacteria,
especially Campylobacter sp. and E. coli (25-27,38), a situa-
tion that threatens to impede the effectiveness of this anti-
microbial group. The significantly more common multidrug
resistance observed here among the quinolone-resistant sal-
monellae compared with the susceptible population (47.4%
vs. 11.5%) is also of concern. This finding suggests that the
use of fluoroquinolones may select for multidrug resistance
among salmonellae and provokes a question of whether the
same could happen among other bacterial species. In that
case, the likelihood of the emergence of notable pathogens,
resistant to fluoroquinolones as well as to other commonly
used drugs, will certainly increase if the consumption of
fluoroquinolones continues to grow. Collectively, these data
indicate that prudent use of the quinolone antimicrobial
group is warranted to prevent further development of resis-
tance and to preserve the usefulness of these valuable drugs.
Table 5. Estimated travel-associated Salmonella infection rates in Finnish travelers
Country
Est. no.
 of trips from 
Finland during
 study months a
No. of
 all isolates
Infection 
rateb
Rate 
ratioc
No. of isolates
 with CIPd MIC 
>0.125 µg/mL
Infection rateb by 
isolates with CIP 
MIC >0.125 µg/mL
Rate ratio c by 
isolates with 
CIP MIC
 >0.125 µg/mL
Thailande,f 38,180 114 3.0 1 31 0.81 1
Spain (incl. 
Canary 
Islands)e,f
391,310 88 0.2 0.08 
(0.057-
0.100)
6 0.02 0.02 (0.008-
0.045)
Turkeye,f 45,427 69 1.5 0.51 
(0.377-
0.686)
3 0.07 0.08 (0.025-
0.266)
Tunisiae 5,526 37 6.7 2.24 
(1.548-
3.249)
0 0 0 (NA)
Estoniae 135,128 32 0.2 0.08 
(0.054-
0.117)
1 0.01 0.01 (0.001-
0.067)
Israelf 23,014 12 0.5 0.17 
(0.096-
0.317)
7 0.30 0.37 (0.165-
0.851)
Malaysiaf 3,747 11 2.9 0.98 
(0.530-
1.826)
3 0.80 0.99 (0.302-
3.225)
aBased on the numbers of Finnish travelers to these countries; data collected from the reports of Statistics Finland.
bInfections per 1,000 trips.
cThailand as the reference country. 95% confidence intervals in parentheses. The rate ratios between Thailand or Malaysia and other destinations were
significant (p values <0.05).
dCIP = ciprofloxacin.
eFive most frequent countries of origin of all Salmonella isolates.
fFive most frequent countries of origin of Salmonella isolates with reduced ciprofloxacin susceptibility (MIC >0.125 µg/mL).Research
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In conclusion, we have shown a dramatic increase in
reduced fluoroquinolone susceptibility in salmonellae from
travelers returning from Southeast Asia. The reduced sus-
ceptibility of salmonellae to the fluoroquinolone group was
significantly associated with multidrug resistance. More-
over, all quinolone-resistant Salmonella isolates had under-
gone a point mutation in the QRDR of the  gyrA gene. In
contrast to previous reports on quinolone resistance in a spe-
cific clone or in a few Salmonella serotypes, the reduced fluo-
roquinolone susceptibility of our isolates was nonclonal.
These data provide further evidence of the rapid spread of
multidrug-resistant pathogens from one continent to
another. The emergence of antimicrobial resistance in any
part of the world may have global implications and is, there-
fore, of universal concern.
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